Sickle Cell Disease Stocks

Biotechnology firms in this cohort focus on the development of curative gene-editing therapies and oral small molecules designed to modify hemoglobin production or prevent the vaso-occlusive crises inherent to sickle cell disease.

As of Oct 23, 2026, Sickle Cell Disease has 5 US-listed companies worth $146B combined. The median member moved +2.5% over the past week; AGIO led at +18.1% and CRSP trailed at +0.3%.